2026-06-14T02:27:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/163132024-09-28T00:07:29Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19610

00925njm 22002777a 4500 dc Santonen, Tiina author Mahiout, Selma author Alvito, Paula author Apel, Petra author Bessems, Jos author Bil, Wieneke author Borges, Teresa author Bose-O'Reilly, Stephan author Buekers, Jurgen author Cañas Portilla, Ana Isabel author Castaño, Argelia author De Alba-González, Mercedes author Domínguez-Morueco, Noelia author Esteban-Lopez, Marta author Falnoga, Ingrid author Gerofke, Antje author González-Caballero, MCarmen author Horvat, Milena author Huuskonen, Pasi author Kadikis, Normunds author Kolossa-Gehring, Marike author Lange, Rosa author Louro, Henriqueta author Martins, Carla author Meslin, Matthieu author Niemann, Lars author Pedraza-Diaz, Susana author Plichta, Veronika author Porras, Simo P author Rousselle, Christophe author Scholten, Bernice author Silva, Maria João author Šlejkovec, Zdenka author Tratnik, Janja Snoj author Joksić, Agnes Šömen author Tarazona, Jose author Uhl, Maria author Van Nieuwenhuyse, An author Viegas, Susana author Vinggaard, Anne Marie author Woutersen, Marjolijn author Schoeters, Greet author 2023-04 One of the aims of the European Human Biomonitoring Initiative, HBM4EU, was to provide examples of and good practices for the effective use of human biomonitoring (HBM) data in human health risk assessment (RA). The need for such information is pressing, as previous research has indicated that regulatory risk assessors generally lack knowledge and experience of the use of HBM data in RA. By recognising this gap in expertise, as well as the added value of incorporating HBM data into RA, this paper aims to support the integration of HBM into regulatory RA. Based on the work of the HBM4EU, we provide examples of different approaches to including HBM in RA and in estimations of the environmental burden of disease (EBoD), the benefits and pitfalls involved, information on the important methodological aspects to consider, and recommendations on how to overcome obstacles. The examples are derived from RAs or EBoD estimations made under the HBM4EU for the following HBM4EU priority substances: acrylamide, o-toluidine of the aniline family, aprotic solvents, arsenic, bisphenols, cadmium, diisocyanates, flame retardants, hexavalent chromium [Cr(VI)], lead, mercury, mixture of per-/poly-fluorinated compounds, mixture of pesticides, mixture of phthalates, mycotoxins, polycyclic aromatic hydrocarbons (PAHs), and the UV-filter benzophenone-3. Although the RA and EBoD work presented here is not intended to have direct regulatory implications, the results can be useful for raising awareness of possibly needed policy actions, as newly generated HBM data from HBM4EU on the current exposure of the EU population has been used in many RAs and EBoD estimations. Int J Hyg Environ Health. 2023 Apr;249:114139. 10.1016/j.ijheh.2023.114139 1618-131X 1438-4639 International journal of hygiene and environmental health 36870229 http://hdl.handle.net/20.500.12105/16313 Chemicals Environmental burden of disease Exposure biomarkers HBM4EU Human biomonitoring Risk assessment How to use human biomonitoring in chemical risk assessment: Methodological aspects, recommendations, and lessons learned from HBM4EU